This study is a non randomized non comparative study with two Siddha formulations Sindhuvallathy Mezhugu and Kalladaippu Kudineer are available in Siddha classical texts existing for longer period. But there is no scientific data is documented about these formulations. This study aimed to evaluate the efficacy of the study drugs for urolithiasis. After the preliminary drug standardization the clinical study is Started at The National Institute of Siddha Tambaram. The primary outcome measure is either the Expulsion of stones or Changes in the number and size of the stones with 45 days drug treatment.

Start Date01 Jun 2012

Sponsor / Collaborator

The Tamil Nadu Dr. M.G.R. Medical University

[+1]

100 Clinical Results associated with Sindhuvallathy mezhugu

100 Translational Medicine associated with Sindhuvallathy mezhugu

100 Patents (Medical) associated with Sindhuvallathy mezhugu

Literatures (Medical) associated with Sindhuvallathy mezhugu

08 Jan 2025·mBio

Interaction of the Wolbachia surface protein with a novel pro-viral protein from Aedes aegypti

Article

Author: Hussain, Mazhar ; Qi, Zhi ; Asgari, Sassan

ABSTRACT Dengue virus (DENV) and other flaviviruses are prevented from replicating in mosquitoes by Wolbachia . To date, several reports have appeared that highlight multiple molecular and cellular pathways involved in the blocking mechanism, which underlines the complicated nature of the mechanism. Here, we developed a hypothesis on whether Wolbachia proteins interact with pro-viral host proteins by using a unique approach to study the antiviral mechanism based on Wolbachia -host protein-protein interaction. We selected Wolbachia surface protein (WSP) for co-immunoprecipitation because of its abundance and possible secretion. We first confirmed WSP’s secretion in mosquito cells and found two host proteins, Ae. aegypti serine-threonine kinase (STK) and synaptic vesicle membrane (SVM) protein VAT-1, and one Wolbachia protein ( w GroEL) interacting with WSP. We examined the role of STK and SVM genes in relation to DENV replication in Ae. aegypti mosquitoes and mosquito cell lines with and without Wolbachia . In DENV-infected Aag2 cells, the expression of SVM and STK was significantly increased. However, although these genes were induced in Wolbachia -infected Aag2 cells, they were downregulated after DENV infection. Silencing of STK , but not SVM , reduced DENV replication in Aag2 cells and mosquitoes. Conversely, RNA activation of STK , by utilizing promoter induction via short activating oligos, resulted in higher DENV replication in Wolbachia -infected and uninfected cell lines. Overall, our findings suggest that STK is a pro-viral gene, and Wolbachia WSP binds to STK, possibly making it less accessible for DENV replication. IMPORTANCEWolbachia is an endosymbiotic bacterium that blocks the replication of arboviruses in transinfected Aedes aegypti mosquitoes. In this study, we focused on identifying the potential interaction of Wolbachia proteins with the host pro-viral proteins. For this, we embarked on identifying the interacting proteins with a major Wolbachia protein, WSP, which is both structural and also secreted into the host cells. An Ae. aegypti STK was identified, which is induced in DENV and Wolbachia -infected cells. Silencing or induction of the gene led to reduced and increased DENV replication in vitro . Consistently, knocking down the gene in mosquitoes resulted in decreased virus replication. We hypothesize that WSP may sequester STK, which is pro-viral, contributing to Wolbachia virus blocking.

01 Jun 2022·Computers in Biology and MedicineQ3 · ENGINEERING & TECHNOLOGY

Lupus nephritis diagnosis using enhanced moth flame algorithm with support vector machines

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Wang, Mingjing ; Hu, Zhongyi ; Chen, Siyuan ; Chen, Huiling ; Chen, Xiaowei ; Liang, Yingqi ; Zhang, Qian ; Shi, Beibei ; Heidari, Ali Asghar

Systemic lupus erythematosus is a chronic autoimmune disease that affects the kidney in most patients. Lupus nephritis (LN) is divided into six categories by the International Society of Nephrology/Renal Pathology Society (ISN/RPS). The purpose of this research is to build a framework for discriminating between ISN/RPS pure class V(MLN) and classes III ± V or IV ± V (PLN) using real clinical data. The framework is developed by merging a hybrid stochastic optimizer, moth-flame algorithm (HMFO), with a support vector machine (SVM), dubbed HMFO-SVM. The HMFO is constructed by enhancing the original moth-flame algorithm (MFO) with a bee-foraging learning operator, which guarantees that the algorithm speeds convergence and departs from the local optimum. The HMFO is used to optimize parameters and select features simultaneously for SVM on clinical SLE data. On 23 benchmark tests, the suggested HMFO method is validated. Finally, clinical data from LN patients are analyzed to determine the efficacy of HMFO-SVM over other SVM rivals. The statistical findings indicate that all measures have predictive capabilities and that the suggested HMFO-SVM is more stable for analyzing systemic LN. HMFO-SVM may be used to analyze LN as a feasible computer-assisted technique.

01 May 2022·International Journal of Drug PolicyQ2 · MEDICINE

Implementation and evaluation of a syringe vending machine trial in Tbilisi, Georgia

Q2 · MEDICINE

Article

Author: Mgebrishvili, Tamar ; Otiashvili, David ; Tabatadze, Mzia ; Vardanashvili, Irina ; Kirtadze, Irma ; Ober, Allison J ; Beselia, Ada

BACKGROUNDSyringe vending machines (SVM) have proven to be an effective vehicle for providing an uninterrupted supply of sterile equipment to PWID, but they have not been implemented or disseminated broadly. The aim of this study was to implement and evaluate outcomes of introducing SVM in Tbilisi, Georgia.METHODSWe installed SVM at five HIV prevention sites in 10 locations in Tbilisi, Georgia and studied implementation over 20 months. We used the RE-AIM framework to assess outcomes across four RE-AIM domains: reach, effectiveness at providing syringe access, adoption and implementation.RESULTSReach. SVM reached 8% of the target population. Effectiveness at Providing Syringe Access. SVM dispensed 14% of all syringes distributed by HIV prevention services. Using SVM was associated with PWID receiving more sterile syringes from HIV prevention outlets. Adoption. All HIV prevention sites (N=5) invited to implement SVM agreed to participate. Sixty one percent of PWID who received SVM access cards used SVM at least once. Women and young PWID were more likely to use SVM compared to other PWID.IMPLEMENTATIONAt some sites adherence of the outreach staff to the operational protocol was suboptimal.CONCLUSIONSSVM are an acceptable, feasible and effective intervention for improving access to sterile injection equipment for PWID. Future research will need to elaborate approaches to build the sense of ownership and improve motivation of the field staff to engage with the new intervention, and to examine strategies for attracting groups of PWID who are not in contact with prevention and treatment services.

100 Deals associated with Sindhuvallathy mezhugu

R&D Status

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EANM2016	Not Applicable	Amyotrophic Lateral Sclerosis	175	SVM (Principal Component Analysis plus Logistic Regression (PCA-LR))	(lvtxbgscvd) = zmkjxbgvvu trolvqttzl (kozisxusis ) View more	-	21 Sep 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sindhuvallathy mezhugu

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation